|
rs74799832
|
|
C |
0.720 |
CausalMutation |
CLINVAR |
Molecular biology of the MEN2 gene.
|
9681850 |
1998 |
|
rs1799939
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A G691S RET polymorphism was present with a higher frequency in radiation-induced epithelial thyroid tumours (55%) than in sporadic tumours (20%) and in control normal thyroid tissues (15%).
|
12085189 |
2002 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A missense mutation was found at T1796A (V599E) in exon 15 in four of the six cell lines and 51 of 207 thyroid tumors (24.6%; 0 of 20 follicular adenoma, 0 of 11 follicular carcinoma, 49 of 170 papillary carcinomas, and 2 of 6 undifferentiated carcinomas).
|
12970315 |
2003 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A missense mutation was found at T1796A (V599E) in exon 15 in four of the six cell lines and 51 of 207 thyroid tumors (24.6%; 0 of 20 follicular adenoma, 0 of 11 follicular carcinoma, 49 of 170 papillary carcinomas, and 2 of 6 undifferentiated carcinomas).
|
12970315 |
2003 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs17879961
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The missense variant I157T was associated with an increased risk of breast cancer (OR 1.4; P=.02), colon cancer (OR 2.0; P=.001), kidney cancer (OR 2.1; P=.0006), prostate cancer (OR 1.7; P=.002), and thyroid cancer (OR 1.9; P=.04).
|
15492928 |
2004 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We isolated genomic DNA from primary thyroid tumors and paired lymph node metastases and performed direct sequencing of exon 15 of the BRAF gene mutation that carries the T1799A mutation.
|
15998781 |
2005 |
|
rs5443
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To elucidate a possible role in the development and course of thyroid tumours of follicular cell origin, C825T polymorphism genotypes and allele frequencies were investigated in a series of adenomas and differentiated carcinomas.
|
16178055 |
2005 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
|
16268813 |
2005 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
|
16268813 |
2005 |
|
rs79658334
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
|
16490247 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent.
|
17054470 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent.
|
17054470 |
2006 |
|
rs5443
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The results strongly suggest that the C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours.
|
17136758 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
rs104894228
|
|
G |
0.710 |
CausalMutation |
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
rs104894228
|
|
A |
0.710 |
CausalMutation |
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
rs104894229
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
rs104894230
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |